hotspot -WSS

hotspot

author：leisure time 2025-10-01 05:39:41 - browse：46766

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： WHO may add ‘noma' to its list of neglected tropical diseases

Wikipedia

hotspot

WSS

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Readout Newsletter: What happened with Sarepta's Duchenne data

Biden administration opens offers in Medicare drug price negotiations

Time to name cancers by genetics, not organ of origin, expert says

Apple Vision Pro: A first look at health apps on the new VR headset

FDA has safety concerns on CRISPR

entertainment

hotspot

Wikipedia

State Dept. review finds Biden bears some blame for Afghanistan failures

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Drug repurposing or repositioning? The language matters

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

How one medical school became remarkably diverse

Traditional Chinese medicine benefits explored in new JAMA study

Affirmative action in medical school literally saved lives

First Opinion Podcast: How to protect health care in times of war

Anesthesiologist group: stop taking Ozempic before surgery

Telehealth options flood the market as retailers push virtual care

leisure time

ARCH Venture Partners is raising $3 billion for a life sciences fund

Paying for Covid pills will soon shift to insurers

Commercial surrogacy can be ethical, despite pope’s claims

Why Sanofi got shellacked over its spinoff

The real point of Kenneth Smith’s execution by nitrogen gas

Physician subsidies by hospitals soar in wake of No Surprises Act

hotspot

Wikipedia

hotspot

leisure time